REP 2139-Ca: Completed Phase II enrollment

Replicor completed enrollment of 12 patients in the open-label, Moldavian Phase II REP 301 trial evaluating once-weekly IV REP 2139-Ca in combination with Pegasys peginterferon alfa-2a. Patients are ...